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Effects of Polyhalogenated Aromatic
Compounds on Porphyrin Metabolism
by Robert H. Hill, Jr.*
Heme production is a vital metabolic process that occurs in the bone marrow and liver. Porphyrins are
unused by-products ofthis biosynthetic process and normally occur in urine and other body fluids in low
concentrations.
Various disorders can disrupt the heme biosynthetic process, causing greater quantities ofporphyrins in
urine. Theporphyrias are agroupofdiseases characterized by excessive porphyrins andother precursors in
urine. Porphyrias may be either hereditary or acquired through exposure to certain drugs or chemicals.
Porphyria cutanea tarda (PCT) is the disease associated with exposure to polyhalogenated aromatic
compounds. The urinary porphyrin pattern is ofgreat value in diagnosing PCT anddefiningthe etiology of
the disease. As this liver disease from chemical damage develops, the urinary pattern progressively
changes. With the development ofarapid and sensitive high-performance liquid chromatography analysis,
urinary porphyrin patterns can beeasilymonitored. Allfree porphyrin acids can bequantitatively analyzed
in less than 15 min.
In our studies ofgroups exposed to porphyrinogenic chemicals, we have not observed clear differences in
the urinary porphyrin patterns ofcaseswhen compared with carefully selected controls. In animal studies,
however, PCT was clearly associated with polybrominated biphenyl exposure. Future evaluation of the
utility of urinary porphyrin patterns as a diagnostic tool will require a cohort that has received a recent,
well-documented exposure and a comparable control population. Assay of erythrocyte uroporphyrinogen
decarboxylase activity will also be needed to define the form of the PCT.
Introduction
The ability to recognize disease in its early stages
before overt symptoms appear is a continuing goal of
medicalscience. Accomplishingthisgoaloftenresults in
treatment which arrests or prevents further develop-
ment of the disease.
Monitoring various biochemical functions may pro-
vide this type ofinformation. Our interest in this area
has been in the evaluation of the heme biosynthetic
pathway under the influence of environmental chemi-
cals via urinary porphyrin analyses. This paper de-
scribes the heme biosynthetic pathway and the changes
that may occur with exposure to polyhalogenated aro-
matic compounds. The importance of recognizing vari-
ous urinary porphyrin patterns by high-performance
liquidchromatography(HPLC)isdiscussed, anddemon-
strated, and suggestions are made for using these
patterns as a diagnostic tool.
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Heme Biosynthesis
The production of heme is a vital metabolic process,
and disturbances inthe biosynthesis ofheme can lead to
a group of diseases known as the porphyrias. Heme is
produced principally in the bone marrow and the liver.
Most heme (85%) is made in the bone marrow and is
used to make hemoglobin for new red blood cells (1).
About 15% ofthe body's heme production occurs in the
liver. This heme is used in making enzymes, including
microsomal cytochrome P450 and other cytochromes.
The biosynthesis of heme, as depicted in Figure 1,
begins in the mitochondrion ofa cell with the condens,-
tionofglycineandsuccinate toproduce8-aminolevulinic
acid (ALA). Two molecules of ALA are used to form
porphobilinogen (PBG), and four molecules ofPBG are
condensed toformuroporphyrinogen (UPG). This mole-
cule is successively decarboxylated and oxidized to
protoporphyrin (PP), whichis oxidized and converted to
heme by insertion of a ferrous ion.
Porphyrins are by-products ofthe biosynthetic path-
way to heme and are derived from oxidation of the
porphyrinogens. The body produces two isomeric types
of porphyrinogens and the corresponding porphyrinsR. H. HILL, JR.
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pes I and III. Reprinted withpernission CHP is characterized as amembrane disease in which
there is damage to the membranes of the cell walls of
the hepatocytes and organelles (i.e., mitochondria, ~rs cannot be converted to heme endoplasmic reticulum) within the liver cell (3,4). The
seless waste products. lype III cause of damage is unknown. Recent reports provide
)orphyrins) are the heme precur- some evidence that polyhalogenated aromatics (i.e.,
al conditions, are efficiently used polybrominated biphenyls [PBBs]) produce changes in
heme. Only traces of the corres- lipid metabolism, which in turn alters membrane struc-
hyrins (oxidized porphyrinogens) ture (5). This change in membrane structure may cause rine. a change in membrane permeability (damage) so that
porphyrins are excreted in the bile capillaries and the
intercellular substance. In addition to these changes,
a group of diseases caused by these porphyrinogenic chemicals or their metabolites long the heme biosynthetic path- cause the induction ofALA synthetase and inhibition of
rized by abnormal and excessive the enzyme uroporphyrinogen decarboxylase (UPD).
r precursors in body fluids and The changes in enzyme activities produce a buildup of
eral types ofporphyria, each with uroporphyrinogen and heptacarboxylporphyrinogen,
oms and biochemical signs. The and these precursors are excreted in the urine where
een associated with exposure to they are easily oxidized to uroporphyrin and hepta-
atic compounds (PHAs) is chronic carboxylporphyrin. A urinary porphyrin pattern in HP). CHP may be a subclinical which these two porphyrins are dominant is particularly
the urinary porphyrin excretion is diagnostic of this enzyme deficiency and PCT (6-9).
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There are two forms of PCT: familial or hereditary
andacquiredorchemicallyinduced(10-12). Itispossible
and important to distinguish between these two forms.
In the hereditary form, at least some family members
exhibit overt or subclinical signs of PCT. Additionally,
the activity of the enzyme UPD is substantially de-
creased in the liver and in the erythrocytes. In the
chemically induced porphyria, there is no evidence of
PCT among relatives, and UPD activity is depressed in
the liver but is normal in the erythrocytes. Measuring
this erythrocyte enzyme activityinsubjects with abnor-
mal porphyrin patterns is necessary to distinguish
between hereditary and chemically induced porphyria.
Various chemicals have been reported to induce PCT
and other subclinical states of CHP in humans. These
include alcohol, estrogens, hexachlorobenzene, 2,3,7,8-
tetrachlorodibenzo-p-dioxin, methyl chloride, lindane
polychlorinated biphenyls (PCBs), polybrominated bi-
phenyls (PBBs) and vinyl chloride. Alcohol and estro-
gens are the most common chemicals which have been
observed to cause PCT (1,3,13-15). In Turkey in the
1950s, several thousand persons contracted PCT and a
"mixed" porphyria from exposure to hexachlorobenzene
(16). Even after 25 years, many of the people still
exhibit signs and symptoms of this porphyria. In
Czechoslovakia, workers from a 2,4,5-T production
plant became ill from exposure to 2,3,7,8-tetrachloro-
dibenzo-p-dioxin (TCDD) (17). At the initial investi-
gation, 20% had PCT and another 21% had uropor-
phyrinuria, but 10years laterthese signsand symptoms
were rare, Isolated cases of PCT and porphyrinuria
from methyl chloride and lindane have also been re-
ported(18-20). Polychlorinatedbiphenyls(PCBs),PBBs,
and vinyl chloride have been reported to produce
subelinical CHP (21-23).
Monitoring Urinary Porphyrin
Patterns
Determining urinary porphyrin patterns is an impor-
tant aid in diagnosing porphyria (6-9). In the early
1970s, Doss pointed outthat thin-layer chromatography
(TLC) provided quantitative and qualitative data that
allowed PCT to be diagnosed from a single urine sample
(6). This same author developed the theory that CHP,
whether hereditary or acquired by chemical exposure,
developed in stages, and these stages are recognizable
by their distinct urinary porphyrin patterns (24). Strik
refined these pattern classifications (Table 1) and has
used these for recognizing early effects from exposure
to porphyrinogenic chemicals (25).
In animals or humans exposed to porphyrinogenic
chemicals, a normalliverandurinaryporphyrinpattern
change into early liver disease and coproporphyrinuria
may be observed. As the liver disease from chemical
damage develops, the urinary patterns change progres-
sively in steps to: a type A pattern in which the
uroporphyrins or heptacarboxylporphyrins are present
in amounts less than coproporphyrin; a type B pattern
Table 1. Urinary porphyrin chromatographic patterns
of chronic hepatic porphyria (CHP).a
Porphyrin distributionb
Pattern classification U/C 7/C U % 7 % (U + 7),%
Nonnal 0.2-0.5 <1 20 5 25
Coproporphrinuria <0.2 <1 20 5 25 Tlype A <1 <1 30 5-15 30-50
Type B >1 <1 30-50 15-20 45-70
TCype C >1 >1 50 20-30 60-80
Type D (porphyria cutanea
tarda, PCT) >1 >1 60 25-35 65-90
aAdapted from Strik, et al. (25).
bU = uroporphyrin; 7 = heptacarboxylporphyrin; C = copro-
porphyrin.
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FIGURE 3. Examples ofthe various types ofurinary porphyrin pat-
terns as determined by HPLC with fluorescence detections. Con-
ditions have been previously reported (9).
in which the concentration ofthe uroporphyrin, but not
that of heptacarboxylporphyrin, becomes greater than
the concentration ofcoproporphyrin; and types C and D
patterns which are characterized by dominant peaks of
uroporphyrin and heptacarboxylporphyrin, both of
which are present in amounts greater than copropor-
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FIGURE 4. Plots of the periodic urinary porphyrin output of groups of female Sherman rats that were given either 1 g/kg or 0 g/kg (control)
of PBB. The urinary porphyrin output is expressed as the ratios of uroporphyrin to coproporphyrin (U/C) and heptacarboxylporphyrin to
coproporphyrin (Hp/C). The urinary porphyrins were determined by a previously reported procedure (9).
phyrin. These latter patterns (C and D) are observed in
porphyria cutanea tarda. As perhaps might be expected,
the uroporphyrin and heptacarboxylporphyrin are the
two porphyrins found in porphyric liver tissue (26).
With the development of HPLC, determining these
urinary porphyrin patterns has become much easier,
less time-consuming, and more adaptable to routine
analysis.
All free porphyrin acids can be quantitatively ana-
lyzed by ion-pair chromatography with isocratic elution
in less than 15 min, and the pattern can be assessed to
identi'fy abnormal hepatic conditions (9) (Fig. 3). These
analyses can be used to follow the development of CHP,
as in Figure 4, where the urinary outputs of groups of
female rats given 1 g/kg of PBB (Firemaster) or 0 glkg
(controls) were followed. CHP becomes evident about 55
to 60 days after dosing, as indicated by the large
increase in uroporphyrin and heptacarboxylporphyrin
and the corresponding ratios of these porphyrins to
coproporphyrin. Between 85 and 100 days, CHP devel-
ops into its most severe form (type D).
It is clear that identifying the urinary porphyrin
pattern may be important in determining chronic liver
disease and that applying this technique in studies of
populations exposed to porphyrinogenic chemicals may
be a key to early recognition of chemically induced
hepatic disorders. Strik recently reported that there
was a clear increase in the incidence of type A urinary
porphyrin patterns among farm families exposed to
PBB when compared with nonexposed farm families
(22). Similarly, Doss found liver damage and an excess
of type A urinary porphyrin patterns among vinyl
chloride chemical workers (23).
In our studies of groups exposed to porphyrinogenic
chemicals, we have not observed the clear differences in
urinary porphyrin patterns that Strik (22) and Doss (23)
observed: 47% and 75% abnormal patterns, respectively
Generally, 80 to 90% of our exposed groups had normal
patterns, and coproporphyrinuria occurred about equally
(5-8%) in cases and controls. Type A patterns (2-12%)
were found in both cases and controls. These patterns
occurred slightly more frequently in cases, but the
differences were not significant. One type B pattern and
one PCT pattern were observed. The apparent lack of
ability to distinguish between cases and controls in our
limited studies does not indicate that urinary porphy-
rims are poor indicators of chemical exposure, since our
study groups were exposed to these chemicals many
years ago and have been removed from that exposure,
and the effects upon the liver (if ever present) were not
present at the time of our studies. This may also reflect
a lack of significant chemical exposure of individuals in
the groups studied.
The reversibility or repair of liver disease and por-
phyria upon removal of chemical exposure is well
supported by the Czechoslovakian study of TCDD-
exposed workers (17). Porphyrinuria or PCT was ini-
tially observed in 40% of this group, but 10 years later
these signs and symptoms were rare. In our animal
studies, the type A porphyrin pattern proved to be only
a normal variant among PBB-dosed animals and
nonexposed controls. Only type B or more advanced
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patterns were clearly associated only with PBB ex-
posure. This does not mean that the type A pattern
observed among the PBB-exposed animals was not
produced by the PBB, but normal variations in control
animals made it impossible to distinguish such effects
with our small groups.
Conclusions
To evaluate the utility ofurinary porphyrin patterns
as a tool for recognizing exposure to PHAs, investiga-
tors must follow a population in which exposure has
beenrecent and well documented. Acomparable control
population should alsobe selected so thatanysignificant
difference in porphyrin patterns and other biochemical
values can be readily discerned.
Urine samples must be preserved properly (9) and
must be analyzed by HPLC (or TLC) with proper
quality control measures to provide the needed specifi-
city. Investigators should also note exposure to alcohol
and estrogenic substances, which are also porphyrino-
genicagents. AllcasesinwhichPCThas beenconfirmed
or is suspected should be assayed for erythrocyte UPD
activity. A normal value, with complementary absence
ofPCT in family members, will likely indicate that the
PCT was acquired from chemical exposure. Perhaps
with the use ofthese and other techniques, chemically
induced disease can be more clearly defined.
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